First in Human Study of TORL-1-23 in Participants with Advanced Cancer

Inclusion Criteria:

• Advanced solid tumor

• Measurable disease, per RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Adequate organ function

Exclusion Criteria:

• Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade ≤1] from theacute toxicities of previous therapy, except treatment-related alopecia orlaboratory abnormalities otherwise meeting eligibility requirements

• Received prior chemotherapeutic, investigational, or other therapies for thetreatment of cancer within 14 days with small molecule and within 28 days withbiologic before the first dose of TORL-1-23

• Progressive or symptomatic brain metastases

• Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active,uncontrolled infection

• History of significant cardiac disease

• History of myelodysplastic syndrome (MDS) or AML

• History of another cancer within 3 years before Day 1 of study treatment, with theexception of basal or squamous cell carcinoma of the skin that has been definitivelytreated. A history of other malignancies with a low risk of recurrence, includingappropriately treated ductal carcinoma in situ (DCIS) of the breast and prostatecancer with a Gleason score less than or equal to 6, are also not excluded

• If female, is pregnant or breastfeeding